AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been recommended for EU approval as a perioperative treatment for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen includes Imfinzi plus chemotherapy before surgery, followed by Imfinzi plus chemotherapy and then Imfinzi alone.
The CHMP’s positive opinion is based on the Phase III MATTERHORN trial, where the Imfinzi-based regimen cut the risk of disease progression, recurrence or death by 29% and reduced the risk of death by 22% versus chemotherapy alone. One- and two-year event-free survival rates and three‑year overall survival rates favored Imfinzi, with an overall survival benefit seen regardless of PD‑L1 status. Safety was similar between treatment arms, and surgery completion rates were comparable.
Imfinzi is already approved in this indication in the US and other countries based on MATTERHORN, and regulatory applications are under review in Japan and several additional markets. The decision positions Imfinzi as a potential first immunotherapy-based perioperative option for early gastric and GEJ cancers in the EU.
AstraZeneca PLC has begun trading its ordinary shares on the New York Stock Exchange, creating a harmonised global listing alongside its existing listings on the London Stock Exchange and Nasdaq Stockholm under the same AZN ticker. The company states this move opens access to the world’s largest capital market and broadens its global investor base.
Management highlights strong recent growth, citing pipeline readouts representing a stated peak revenue opportunity of over $10 billion and reiterating confidence in reaching a 2030 ambition of $80 billion in annual revenue and launching 20 new medicines. AstraZeneca’s UK and Swedish listings and index memberships remain unchanged, while its prior American Depositary Share listing ceased as ordinary share trading on the NYSE commenced, and its US dollar bonds are also transitioning to trade on the NYSE.
AstraZeneca PLC and AstraZeneca Finance LLC have filed Form 25 to voluntarily remove multiple securities from listing and registration on The Nasdaq Stock Market. The filing covers AstraZeneca American Depositary Shares representing one half of an ordinary share of 25¢ each, the underlying ordinary shares, and a wide range of AstraZeneca and AstraZeneca Finance senior notes with maturities from 2026 through 2051, many of which carry guarantees by AstraZeneca PLC. The companies certify they have complied with Nasdaq’s rules and the requirements of SEC Rule 12d2-2(c) for voluntary withdrawal, and the notification is signed by AstraZeneca PLC’s Company Secretary and an AstraZeneca Finance LLC Director on January 30, 2026.
AstraZeneca has entered a major collaboration with CSPC Pharmaceuticals to expand its weight management portfolio for obesity and type 2 diabetes across eight programmes. The deal gives AstraZeneca exclusive rights outside China to CSPC’s once-monthly injectable weight management portfolio, including clinical-ready GLP1R/GIPR agonist SYH2082 and three preclinical assets.
CSPC will receive an upfront payment of $1.2 billion, and is eligible for up to $3.5 billion in development and regulatory milestones, plus additional commercial milestones and tiered royalties. CSPC will lead development of four programmes through Phase I, after which AstraZeneca will take over development and commercialisation outside China. CSPC retains rights in China, Taiwan, Hong Kong and Macau, with an option for AstraZeneca to co-commercialise after approval. The transaction is expected to close in the second quarter of 2026, subject to customary conditions and regulatory clearances.
AstraZeneca plans to invest $15 billion in China through 2030 to expand medicines manufacturing and research and development. The company aims to strengthen capabilities in cell therapy and radioconjugates, supporting treatments for cancer, blood disorders, autoimmune diseases, and other conditions.
The investment will extend AstraZeneca’s China network from drug discovery and clinical development to large-scale production, building on existing R&D centers in Beijing and Shanghai and manufacturing sites in Wuxi, Taizhou, Qingdao, and Beijing. The company expects its highly skilled workforce in China to grow beyond 20,000, creating thousands of additional jobs across the healthcare ecosystem.
AstraZeneca PLC is reorganising its US market presence by completing a direct listing of its ordinary shares and US debt securities on the New York Stock Exchange. The move is part of a shareholder approved plan to create a harmonised listing structure that supports a single global listing framework for investors.
The company has given notice that its American Depositary Shares, which represent ordinary shares on a two-for-one basis, and certain debt securities currently listed on Nasdaq are expected to cease trading there on 30 January 2026. AstraZeneca’s ordinary shares and these debt securities are expected to begin trading on the NYSE on 2 February 2026 under the ticker symbol AZN. After these changes, investors will be able to trade ordinary share interests across the London Stock Exchange, Nasdaq Stockholm and the NYSE.
AstraZeneca PLC reports a leadership change in its investor relations function. The company has appointed Joris Silon as Head of Investor Relations, effective 1 March 2026, succeeding Andy Barnett. Joris moves into this role from his position as country president of AstraZeneca US, where he led and delivered significant growth in the company’s largest market, and he will be based in Cambridge, UK. He brings extensive pharmaceutical experience, having joined AstraZeneca in 2000 and held leadership roles across Asia, Europe and the US. Chief Financial Officer Aradhana Sarin highlighted his experience and thanked Andy Barnett for his leadership of the Investor Relations team over the past four years as he transitions to a new role within the company.
AstraZeneca reported that Enhertu (trastuzumab deruxtecan), developed with Daiichi Sankyo, has received US FDA Breakthrough Therapy Designation as a post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer who have residual invasive disease after neoadjuvant therapy and are at high risk of recurrence. The designation is based on positive Phase III DESTINY‑Breast05 trial results, which were presented at the 2025 ESMO Congress and published in The New England Journal of Medicine. DESTINY‑Breast05 enrolled 1,635 patients and compares Enhertu to trastuzumab emtansine (T‑DM1), the current standard in this setting, using invasive disease‑free survival as the primary endpoint. This is the tenth Breakthrough Therapy Designation for Enhertu, reinforcing its strategic importance within AstraZeneca’s growing oncology and breast cancer portfolio.